Pure Biologics Spólka Akcyjna (PUR) - Net Assets
Based on the latest financial reports, Pure Biologics Spólka Akcyjna (PUR) has net assets worth zł-19.39 Million PLN (≈ $-5.34 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (zł1.33 Million ≈ $366.04K USD) and total liabilities (zł20.72 Million ≈ $5.70 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PUR PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | zł-19.39 Million |
| % of Total Assets | -1457.67% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 482.42 |
Pure Biologics Spólka Akcyjna - Net Assets Trend (2016–2024)
This chart illustrates how Pure Biologics Spólka Akcyjna's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see how much is Pure Biologics Spólka Akcyjna worth.
Annual Net Assets for Pure Biologics Spólka Akcyjna (2016–2024)
The table below shows the annual net assets of Pure Biologics Spólka Akcyjna from 2016 to 2024. Also explore PUR net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | zł-13.12 Million ≈ $-3.61 Million |
-792.87% |
| 2023-12-31 | zł1.89 Million ≈ $520.98K |
-89.65% |
| 2022-12-31 | zł18.30 Million ≈ $5.04 Million |
-53.66% |
| 2021-12-31 | zł39.49 Million ≈ $10.87 Million |
+1467.72% |
| 2020-12-31 | zł-2.89 Million ≈ $-794.54K |
-140.02% |
| 2019-12-31 | zł7.21 Million ≈ $1.99 Million |
+224.80% |
| 2018-12-31 | zł2.22 Million ≈ $611.22K |
+958.71% |
| 2017-12-31 | zł209.77K ≈ $57.73K |
-32.70% |
| 2016-12-31 | zł311.70K ≈ $85.78K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Pure Biologics Spólka Akcyjna's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11193107425.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | zł375.00K | % |
| Other Components | zł98.87 Million | % |
| Total Equity | zł-13.12 Million | 100.00% |
Pure Biologics Spólka Akcyjna Competitors by Market Cap
The table below lists competitors of Pure Biologics Spólka Akcyjna ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Toyo Ventures Holdings Bhd
KLSE:7173
|
$8.33 Million |
|
Batero Gold Corp
V:BAT
|
$8.33 Million |
|
Moatable Inc
NYSE:MTBLY
|
$8.34 Million |
|
BEDFORD METALS CORP.
F:O8D
|
$8.34 Million |
|
One Click Group Ltd
AU:1CG
|
$8.32 Million |
|
Courtois S.A
PA:COUR
|
$8.32 Million |
|
Korporacja Gospodarcza efekt S.A
WAR:EFK
|
$8.32 Million |
|
Snipp Interactive Inc
V:SPN
|
$8.31 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pure Biologics Spólka Akcyjna's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,893,000 to -13,116,000, a change of -15,009,000 (-792.9%).
- Net loss of 19,435,000 reduced equity.
- Other factors increased equity by 4,426,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | zł-19.43 Million | -148.18% |
| Other Changes | zł4.43 Million | +33.75% |
| Total Change | zł- | -792.87% |
Book Value vs Market Value Analysis
This analysis compares Pure Biologics Spólka Akcyjna's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | zł0.27 | zł2.67 | x |
| 2017-12-31 | zł0.18 | zł2.67 | x |
| 2018-12-31 | zł1.89 | zł2.67 | x |
| 2019-12-31 | zł4.73 | zł2.67 | x |
| 2020-12-31 | zł-1.75 | zł2.67 | x |
| 2021-12-31 | zł17.78 | zł2.67 | x |
| 2022-12-31 | zł8.24 | zł2.67 | x |
| 2023-12-31 | zł0.59 | zł2.67 | x |
| 2024-12-31 | zł-3.76 | zł2.67 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pure Biologics Spólka Akcyjna utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-277.19%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -138.89% | -33.59% | 1.35x | 3.05x | zł-464.10K |
| 2017 | -196.75% | -42.04% | 0.74x | 6.32x | zł-433.70K |
| 2018 | -31.04% | -7.23% | 1.45x | 2.96x | zł-911.43K |
| 2019 | -65.22% | -28.08% | 0.77x | 3.02x | zł-5.43 Million |
| 2020 | 0.00% | -2116.26% | 0.03x | 0.00x | zł-11.82 Million |
| 2021 | -33.10% | -5146.06% | 0.01x | 1.20x | zł-17.02 Million |
| 2022 | -144.13% | -3983.69% | 0.02x | 1.80x | zł-28.20 Million |
| 2023 | -1885.58% | -37572.63% | 0.00x | 12.01x | zł-35.88 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | zł-18.12 Million |
Industry Comparison
This section compares Pure Biologics Spólka Akcyjna's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $110,433,153
- Average return on equity (ROE) among peers: -187.62%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pure Biologics Spólka Akcyjna (PUR) | zł-19.39 Million | -138.89% | N/A | $8.33 Million |
| Bioton S.A. (BIO) | $582.00 Million | -21.77% | 0.51x | $85.43 Million |
| Captor Therapeutics S.A. (CTX) | $96.32 Million | -37.26% | 0.17x | $107.79 Million |
| Mabion S.A. (MAB) | $3.73 Million | -1497.08% | 23.47x | $34.61 Million |
| Molecure S.A. (MOC) | $141.14 Million | -9.67% | 0.07x | $44.23 Million |
| Nanogroup SA (NNG) | $-252.70K | 0.00% | 0.00x | $22.00 Million |
| Pharmena S.A. (PHR) | $8.98 Million | -45.66% | 0.29x | $9.53 Million |
| PolTREG S.A. (PTG) | $101.04 Million | -1.95% | 0.22x | $26.05 Million |
| Ryvu Therapeutics SA (RVU) | $3.13 Million | -76.24% | 4.75x | $101.81 Million |
| Synthaverse S.A. (SVE) | $57.81 Million | 1.02% | 1.09x | $60.37 Million |
About Pure Biologics Spólka Akcyjna
Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use. Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFß1 complex; PB004, an anticancer drug based on an anti-ROR1 antibody; and PB003A, a therapy that targets the aVß8 integrin. The company was founded… Read more